Stay Critical, Investors
Toung also noted Celgene's steep discounting of Otezla, a treatment for plaque psoriasis and psoriatic arthritis, could pressure margins moving forward. The company cited a strategy of lowering the price to boost sales among large institutions and could be a strategy of being placed ahead of biologic drugs as a treatment, which may prove successful but definitely requires close monitoring moving forward.
On the positive side, the analyst is encouraged by Celgene's "formidable" new drug pipeline along with new indications for existing drugs.
Finally, Toung pointed out that shares of Celgene have risen a "strong" 23 percent over the past year and are now trading at a valuation of 14.9x his 2018 earnings per share estimate. This multiple represents a premium above other pharmaceutical stocks that the analyst covers at 13.4x.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.